Literature DB >> 2759787

The blood-retinal barrier in chloroquine retinopathy.

M F Raines1, S K Bhargava, E S Rosen.   

Abstract

Chloroquine retinopathy can result in devastating loss of vision. To date, there are no effective and reliable methods of detecting the toxicity at an early stage when retinopathy may be reversible. Chloroquine is deposited in the retinal pigment epithelium, which forms part of the blood-retinal barrier (BRB). By vitreous fluorophotometry we have shown that there is breakdown of the BRB in chloroquine retinopathy. However, in asymptomatic patients who had received varying amounts of hydroxychloroquine (up to 1067 g), the BRB remained intact.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2759787

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  Permeability of the blood-retinal barrier in healthy humans. European Concerted Action on Ocular Fluorometry.

Authors:  H J Van Schaik; B Heintz; M Larsen; E Leite; V Rosas; R Schalnus; J A Van Best
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-10       Impact factor: 3.117

2.  Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.

Authors:  Michelle Petri; Marwa Elkhalifa; Jessica Li; Laurence S Magder; Daniel W Goldman
Journal:  Arthritis Rheumatol       Date:  2020-01-07       Impact factor: 10.995

3.  Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis.

Authors:  Rodolfo Thomé; Adriel S Moraes; André Luis Bombeiro; Alessandro dos Santos Farias; Carolina Francelin; Thiago Alves da Costa; Rosária Di Gangi; Leonilda Maria Barbosa dos Santos; Alexandre Leite Rodrigues de Oliveira; Liana Verinaud
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

4.  Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration.

Authors:  Patrick M Chen; Zoë J Gombart; Jeff W Chen
Journal:  Cell Biosci       Date:  2011-03-08       Impact factor: 7.133

Review 5.  Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review.

Authors:  A Geamănu Pancă; A Popa-Cherecheanu; B Marinescu; C D Geamănu; L M Voinea
Journal:  J Med Life       Date:  2014-09-25

6.  Screening for chloroquine maculopathy in populations with uncertain reliability in outcomes of automatic visual field testing.

Authors:  Paradee Kunavisarut; Pimploy Chavengsaksongkram; Aniki Rothova; Kessara Pathanapitoon
Journal:  Indian J Ophthalmol       Date:  2016-10       Impact factor: 1.848

7.  Hydroxychloroquine for treatment of rheumatoid arthritis: multifocal electroretinogram and laser flare-cell photometry study.

Authors:  Stefano Sebastiani; Michela Fresina; Mauro Cellini; Emilio C Campos
Journal:  Clin Ophthalmol       Date:  2017-04-11

8.  Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.

Authors:  Xuesong Chen; Jonathan D Geiger
Journal:  Cell Signal       Date:  2020-07-03       Impact factor: 4.315

Review 9.  Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.

Authors:  Massimo Nicolò; Lorenzo Ferro Desideri; Matteo Bassetti; Carlo Enrico Traverso
Journal:  Int Ophthalmol       Date:  2020-09-18       Impact factor: 2.031

Review 10.  Wide field retinal imaging and the detection of drug associated retinal toxicity.

Authors:  Giulia Corradetti; Sara Violanti; Adrian Au; David Sarraf
Journal:  Int J Retina Vitreous       Date:  2019-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.